Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib-Reference-Cited by-同舟云学术

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

Published:2016-09-15 Issue:12 Volume:91 Page:1206-1214
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Cortes Jorge E.¹,Khoury Hanna J.²,Kantarjian Hagop M.¹,Lipton Jeff H.³,Kim Dong‐Wook⁴,Schafhausen Philippe⁵,Matczak Ewa⁶,Leip Eric⁷,Noonan Kay⁸,Brümmendorf Tim H.⁵⁹,Gambacorti‐Passerini Carlo¹⁰

Affiliation:

1. University of Texas MD Anderson Cancer CenterHouston Texas

2. Winship Cancer Institute of Emory UniversityAtlanta Georgia

3. Princess Margaret HospitalToronto Ontario

4. Seoul St. Mary's HospitalSeoul South Korea

5. Department of Internal Medicine IIHubertus Wald Tumor Center, University Cancer Center HamburgHamburg Germany

6. Pfizer IncNew York New York

7. Pfizer IncCambridge Massachusetts

8. Pfizer IncGroton Connecticut

9. Universitätsklinikum RWTH AachenAachen Germany

10. University of Milano‐BicoccaMonza Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24536

Reference29 articles.

1. Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis

2. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

3. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

4. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

5. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia;Frontiers in Oncology;2024-08-26

2. Exploring treatment decision-making in chronic myeloid leukemia in chronic phase;Frontiers in Oncology;2024-07-01

3. Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients;Frontiers in Oncology;2024-06-24

4. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-05

5. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study;Leukemia Research;2024-04